ClinicalTrials.gg
RecruitingNCT06606808NAVIGATEUpdated Mar 5, 2025

Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

A Phase 1/2 interventional study of Risankizumab-800CW 4.5 mg and Risankizumab-800CW 15 mg in Ulcerative Colitis (UC) and Crohn Disease (CD), sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by University Medical Center Groningen · Phase 1/2, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Colitis, Ulcerative with a site in Netherlands — 25 open to participants now, 44 under way, 21 of them phase 3. Colitis, Ulcerative · Netherlands.

Planned enrollment
133rd of 139
18 · median 165
Started
2024
with 6 others
Phase 1/2
4 of 164
3 open now
Primary completion
2025-08
later than 8 of 43 live
Registered
148th of 164
by date
Lead sponsor
6 of 164
University Medical Center Groningen

Among the 164 studies in Colitis, Ulcerative with a site in Netherlands, this one is the 133rd largest by planned enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 8 of the 43 other live ones, and was the 148th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

25 of the 164 studies in Colitis, Ulcerative with a site in Netherlands are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Colitis, Ulcerative with a site in Netherlands, or all of them as a file.
02

Study summary

Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor. Primary non-response to risankizumab is high in both CD and UC. Currently, there are no predictors of response to risankizumab and the actual mechanism of action has not yet been elucidated. To gain better understanding of the drug targeting of risankizumab in IBD, the University Medical Center Groningen (UMCG) developed fluorescently labeled risankizumab (risankizumab-800CW). This study aims to assess the safety and the optimal dose of risankizumab-800CW to visualize and potentially quantify the local drug concentration and predict treatment response in IBD patients using in vivo and ex vivo fluorescence molecular imaging (FMI).

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Crohn Disease (CD)

Keywords

  • Fluorescence Molecular Endoscopy
  • Inflammatory Bowel Disease
  • Risankizumab-800CW
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for part A:

  • Established IBD diagnosis
  • Active disease: clinically active disease of the bowel is defined clinically as at least mild activity using dedicated scoring indices or biochemically active disease as defined by a fecal calprotectin > 60 μg/g
  • Patients must be eligible for risankizumab therapy
  • Minimum age of 18 years
  • Written
  • Clinical indication for an endoscopic procedure

Inclusion Criteria for part B:

  • Established IBD diagnosis
  • Patients must be on risankizumab therapy for at least 14 weeks
  • Minimum age of 18 years
  • Written informed consent
  • Clinical indication for an endoscopic procedure

Exclusion Criteria for part A:

  • A female study patient who is pregnant or provides breastfeeding
  • A female study patient of premenopausal age who does not use any reliable form of at the time of risankizumab-800CW administration and the following 10 weeks
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent
  • Prior anti-IL23-specific therapy (IL23/IL12 combination therapy is not an exclusion criteria)
  • Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations)

Exclusion Criteria for part B:

  • A female study patient who is pregnant or provides breastfeeding
  • A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent
  • Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    4.5 mg risankizumab-800CW

    Patients receive 4.5 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure

    Drug: Risankizumab-800CW 4.5 mg

  • Experimental
    15 mg risankizumab-800CW

    Patients receive 15 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure

    Drug: Risankizumab-800CW 15 mg

  • Experimental
    25 mg risankizumab-800CW

    Patients receive 25 mg risankizumab-800CW and undergo a Fluorescence Molecular Imaging procedure

    Drug: Risankizumab-800CW 25 mg

  • Experimental
    14 weeks or more of risankizumab therapy and optimal dose risankizumab-800CW

    Patients who are treated with risankizumab for at least 14 weeks are enrolled in this arm. This can be patients who already joined in the dose finding part of the study or new patients. These patients will receive the optimal dose risankizumab-800CW and will undergo aFluorescence Molecular Imaging procedure

    Drug: Risankizumab-800CW optimal dose

Interventions

  • DrugRisankizumab-800CW 4.5 mg

    Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

  • DrugRisankizumab-800CW 15 mg

    Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

  • DrugRisankizumab-800CW 25 mg

    Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

  • DrugRisankizumab-800CW optimal dose

    Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.

06

What researchers measure

Primary outcomes

  1. Determine the safety of risankizumab-800CW in IBD

    Evaluating possible (severe) adverse events (SAE and AEs)

    Time frame: 2-3 days after administration (day of FME procedure)

  2. Blood pressure

    Systolic and diastolic in millimeters of mercure (mmHg)

    Time frame: Five minutes before, and five and sixty minutes after tracer administration

  3. Heart rate

    Beats per minute

    Time frame: Five minutes before, and five and sixty minutes after tracer administration

  4. Temperature

    Degrees Celsius

    Time frame: Five minutes before, and five and sixty minutes after tracer administration

  5. Investigate the feasibility of using ex vivo FMI to detect risankizumab-800CW

    Evaluating the performance of ex vivo FMI for detecting risankizumab-800CW signals. This evaluation will be based on mean fluorescence intensities (MFIs) of biopsies and fluorescence/light sheet microscopy.

    Time frame: 12 months

  6. Investigate the feasibility of using FME to detect risankizumab-800CW signals_1

    Evaluating the performance of FME for detecting risankizumab-800CW signals. This evaluation will be based on MDSFR/SFF measurements.

    Time frame: 12 months

  7. Investigate the feasibility of using FME to detect risankizumab-800CW signals_2

    Evaluating the performance of FME for detecting risankizumab-800CW signals. This evaluation will be based on a visual evaluation during FME (visible signal yes/no).

    Time frame: 12 months

  8. Investigate the feasibility of using FME to detect risankizumab-800CW signals_3

    Evaluating the performance of FME for detecting risankizumab-800CW signals. This evaluation will be based on TBR/CNR calculations.

    Time frame: 12 months

  9. Determining the optimal imaging dose of risankizumab-800CW

    The optimal dose will be based on the risankizumab-800CW signals during FME and ex vivo FMI

    Time frame: 12 months

Secondary outcomes

  1. Investigate a potential correlation of in vivo fluorescence signal intensities and target saturation to clinical response/remission after 14 weeks of risankizumab therapy regimen in patients with IBD

    Evaluation of the potential correlation in vivo will be based on in vivo fluorescence images and the MDSFR/SFF measurements before and after at least 14 weeks of risankizumab treatment

    Time frame: 12 months

  2. Investigate a potential correlation of ex vivo fluorescence signal intensities and target saturation to clinical response/remission after 14 weeks of risankizumab therapy regimen in patients with IBD

    Evaluation of the potential correlation ex vivo will be based on MFIs of biopsies, fluorescence microscopy results, and tracer concentrations inside biopsies before and after at least 14 weeks of risankizumab treatment

    Time frame: 12 months

  3. Quantify the fluorescence signals of the tracer in vivo by using single-fiber reflectance/single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlate these measurements to tracer dose, in vivo fluorescence intensities and inflammation severity

    Quantification of MDSFR/SFF measurements in inflamed tissue compared to measurements in non-inflamed tissue. Positive correlation between MDSFR/SFF measurements and dose/inflammation severity?

    Time frame: 12 months

  4. To correlate ex vivo fluorescence signals to inflammation severity and tracer dose based on histopathological examination inside the obtained biopsies

    Histologically ascertained tissue types (qualitative): Normal (non-inflamed) ileal, colon and rectal tissue inflamed ileum, colon and rectum tissue Random ''high-fluorescent'' tissue Random ''Non-fluorescent'' tissue

    Time frame: 12 months

  5. To assess tracer stability, tracer distribution and tracer concentration, and to identify the composition of immune cells ex vivo to learn more about risankizumab mucosal target cells

    Fluorescence (confocal) microscopy with additional use of immune panels and spatial transcriptomics analysis (before and after at least 14 weeks of risankizumab treatment). Measurements of the risankizumab-800CW concentration by light-sheet microscopy after tissue clearing, insights in risankizumab target cells and presence of immune cells inside the biopsies and blood samples by flow cytometry and assessment of tracer stability by Western Blot

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Aug 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 23, 2024
StartActual
Nov 8, 2024
Primary completionEst.
Aug 2025
CompletionEst.
Dec 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06606808
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Nov 8, 2024
Primary completion
Aug 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 5, 2025

Study contacts

Wouter B Nagengast, MD, PharmD, PhD
Contact
w.b.nagengast@umcg.nl
+31(0)503612620

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion